Search
Calcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalCalcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D3. It is produced in the body after series...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersGlutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalA tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Flunisolide
go.drugbank.com/drugs/DB00180ApprovedFlunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersCevimeline
go.drugbank.com/drugs/DB00185ApprovedCevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesBortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigationalBortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome ...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, P-glycoprotein substratesBetaxolol
go.drugbank.com/drugs/DB00195ApprovedInvestigationalA cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Synonyms: 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesTroglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesErythromycin
go.drugbank.com/drugs/DB00199ApprovedInvestigationalVet approvedErythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spi...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsDofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical ...
Synonyms: beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigationalTrospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination,...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors